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Background. The number of patients starting renal replace-
ment therapy (RRT) for end-stage renal disease (ESRD) in
the United Kingdom rises annually. Patients are increasingly
elderly with a greater prevalence of comorbid illness. Unad-
justed survival, from the time of starting RRT, is not improving.
The United Kingdom Renal Association has published recom-
mended standards of treatment, which all United Kingdom
nephrologists strive to attain. This study was devised to define
the impact of attaining recommended treatment standards, ad-
justing for patient age and comorbid illnesses, upon survival
on RRT in the United Kingdom population.
Methods. A prospective, registry based, observational study
of all patients starting RRT in Scotland over a 1-year period,
followed for the first 2 years of RRT.
Results. Of the 523 patients who were studied, 217 (41.5%)
had died by 2 years of follow-up, 32% excluding deaths within
the first 90 days. Age, comorbidity, weight when starting RRT,
and attaining the recommended standards for albumin and
hemoglobin had a significant impact upon survival.
Conclusion. This study has emphasized the very high mortal-
ity of patients starting RRT in Scotland. By paying close atten-
tion to the attainment of recommended standards of care for
patients with ESRD, it may be possible to improve upon cur-
rent mortality figures. The monitoring of such success is only
possible if correction is made for age and comorbidity.
The number of patients starting renal replacement
therapy (RRT) for end-stage renal disease (ESRD) con-
tinues to rise annually. There is evidence that this is
largely due to increased access to RRT for older patients
with greater comorbidity, treatment that previously may
not have been available to them. The reported crude sur-
vival of patients treated by RRT is not improving, proba-
bly because of this increasing age and infirmity of the
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RRT population. When survival is adjusted for age and
primary renal diagnosis (PRD), however, improvements
are seen in survival across Europe [1] and the United
States [2].
One of the challenges currently facing nephrologists
is to improve the survival of an infirm RRT population
by optimizing their treatment.
In 1995, the Renal Association of the United Kingdom
(UKRA) published a consensus document of recom-
mended standards for the treatment of adult patients
with ESRD [3], an expanded second edition was pub-
lished in 1997 [4]. The purpose of this document was
to provide recommended standards for optimal clinical
practices to guide nephrologists and thereby improve
patient outcomes. Similarly, in the United States, the
National Kidney Foundation established the Dialysis
Outcomes Quality Initiative (DOQI) in 1995 [5].
The frequency of comorbid illness amongst the inci-
dent RRT population is rising [6, 7]. The presence of
illnesses such as diabetes, atherosclerotic cardiac and
cerebral disease, or malignancy have long been recog-
nized to confer an increased mortality risk in the ESRD
population [8, 9]. The effect of comorbidity upon at-
taining recommended treatment standards is not well
described.
Large registries report the survival of patients treated
by RRT. In the United States, the United States Renal
Data System (USRDS) reports no statistics relating to
the first 90 days of treatment but reports details of the
effects of standards of care. European registries while
not systematically excluding the first 90 days of treatment
cannot claim with certainty to have registered all patients
dying within this period. Such patients are difficult to
identify particularly using retrospective methods and so
actual mortality probably exceeds those estimates avail-
able. The Scottish Renal Registry (SRR), while reporting
upon all patients receiving RRT for ESRD in Scotland,
does not yet routinely take into account comorbid ill-
nesses.
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Table 1. Mode of presentation
for renal replacement therapy (RRT)
Presentation
Planned Permanent vascular or peritoneal access
ready for use for first RRT
Unplanned Follow-up by nephrologist for 1 month,
steady progression to end-stage, no
permanent access
Acute renal failure Presentation with presumed acute renal
failure but failure to recover function
Acute on chronic Follow-up by nephrologist for 1 month,
unexpected acute deterioration in
function to reach end-stage
End-stage Require RRT within 1 month of
presentation to a nephrologist
The purpose of this study was to prospectively inves-
tigate all patients starting RRT in a defined United
Kingdom population, to assess the impact of attaining
recommended treatment standards for hemoglobin con-
centration, serum albumin and hemodialysis adequacy
upon mortality, and to adjust this assessment for age,
burden of comorbid illnesses, and other factors, which
might influence survival and standard attainment.
METHODS
Between October 1, 1997 and September 30, 1998, all
adult patients starting RRT for ESRD in Scotland’s 11
adult renal units were registered when they started RRT
and their treatment was assessed over the next 2 years.
Data relating to attainment of treatment standards were
collected for each patient after 3, 6, 9, 12, and 18 months’
duration of treatment.
Patients were identified weekly by one of us contacting
a liaison person in each unit. A monthly checklist was
circulated to each unit to ensure no patients had been
missed. The data routinely collected by the SRR were
augmented by data collected at each site by a single
medically qualified observer (W.M.) from patients, case
notes, and, where available, renal unit computer systems,
and entered directly on to the Registry via a secure
modem. Baseline and follow-up information were col-
lected in the same way. The same single observer scored
patients’ comorbidity and allocated them to groups ac-
cording to presentation and diagnosis, at the time of
starting RRT. The data collected at baseline were age,
gender, race, primary renal diagnosis, comorbidity, mode
and access for RRT, mode of presentation, duration of
care by a nephrologist prior to starting RRT, weight,
hemoglobin, and albumin. The SRR does not routinely
collect data pertaining to duration of care by a nephrolo-
gist prior to the initiation of RRT, comorbidity, weight,
or serum albumin. The patients were registered on the
day they started RRT, except those failing to recover
from presumed acute renal failure, who were registered
Table 2. Charlson comorbidity score
Weight Condition
1 Myocardial Infarct
CCF
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Peptic ulcer disease
Mild liver disease
Diabetes
2 Hemiplegia
Moderate or severe renal disease
Diabetes with end-organ damage
Any tumour (solid tumour without metastases
diagnosed in past 5 years)
Leukemia (acute and chronic and polycythemia vera)
Lymphoma (includes Hodgkins, Waldenstroms,
myeloma, lymphosarcoma)
3 Moderate or severe liver disease (cirrhosis, portal
hypertension, varices)
6 Metastatic solid tumor
HIV
when the physician caring for them considered they
would require permanent RRT. Patients were prospec-
tively entered into five groups according to their mode
of presentation for RRT (Table 1) as previously de-
scribed [10]. Follow-up was measured in months from
the time the patient was first seen by a nephrologist to
the time of their first RRT; thus, follow-up is the period
under the care of a nephrologist prior to starting RRT.
Patients were grouped according to comorbid condi-
tions present when starting RRT using the Charlson in-
dex of comorbidity (Table 2) [11, 12]. The Charlson
index was used excluding age, which was entered into
the analyses as a separate variable. All patients had se-
vere renal disease by definition and therefore the two
points usually accorded for this diagnosis were disre-
garded. Angina is not included within the Charlson scor-
ing system and was analyzed separately.
A primary renal diagnosis code was chosen from the
list issued by the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA). Di-
agnoses in the ERA-EDTA list have previously been
placed into seven categories: (1) primary glomerulo-
nephritis, (2) interstitial disease, (3) diabetes, (4) hyper-
tensive nephropathy, (5) atherosclerotic renal disease, (6)
other multisystem diseases, and (7) unknown cause [10].
Serum albumin was analyzed using bromocresol green
in all but 17 (3.2%) patients in whom bromocresol purple
was employed. Urea reduction ratio was calculated in
all renal units using the “stop dialysate flow method”
[13]. The attained serum albumin, hemoglobin and urea
reduction ratio for each individual were recorded at each
of 3, 6, 9, 12, and 18 months’ duration of RRT or until
death. Examination of the mean values at each time
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Table 3. Number and % of patients dying in the first 2 years of
renal replacement therapy (RRT)
Overall mortality Excluding 90 day
Duration of RRT N  523 deaths N  450
90 days 14% 73 — —
6 months 19.9% 104 6.9% 31
1 year 27.5% 144 15.8% 71
18 months 35% 183 24.4% 110
2 years 41.5% 217 32% 144
point, both for patients who survived and those who
died, showed that there was no long-term decline in
those patients who died.
For univariate analyses chi square, Kruskal Wallis or
t tests were used where appropriate to identify factors
associated with death within 2 years of starting RRT.
Cox regression analysis was employed for multivariate
analyses of factors associated with length of survival.
Serum albumin, hemoglobin, and urea reduction ratios
were analyzed as time-related covariates in the Cox re-
gression analysis. Thus, each patient was analyzed ac-
cording to whether the recommended standards had
been attained at each time point. A 5% significance level
was employed throughout. All statistical analyses were
performed using SPSS for windows version 9.0.
RESULTS
A total of 542 patients entered the study. After 2 years
2 (0.4%) patients had been lost to follow-up and 17
(3.1%) patients had unexpectedly recovered indepen-
dent native renal function. These patients are excluded
from the analyses discussed here. Fifty-four patients had
functioning renal transplants by the end of 2 years of
treatment; these patients are excluded from the survival
analysis but included in the descriptive statistics.
Of the 523 patients studied, 217 (41.5%) were dead
by the end of 2 years of follow-up. Excluding deaths
within the first 90 days of RRT, mortality after 1 year
was 15.8% and 2-year mortality was 32% (Table 3). The
unadjusted mortality in the first year of RRT was 27.5%
and in the second year 19.3% (73 of the 379 patients
who survived the first year of RRT) (see Fig. 1).
Cardiovascular or vascular disease elsewhere was re-
sponsible for the death of 43.3% (94 patients) of all
patients dying within the first 2 years of starting RRT.
Infection was the primary cause of death for 13.8% (30
patients). Death followed withdrawal of RRT in 15.7%
(34 patients) either through patient choice, medical deci-
sion, or a combination of the two. The withdrawal of
treatment was always in the face of intractable comorbid
disease or disability. Malignant disease was the primary
cause of death for 11.5% (25 patients) and of these 11
(5% of the total cohort) died as a consequence of multi-
ple myeloma which had been their primary renal disease.
Fig. 1. Survival from time of starting renal replacement therapy (RRT).
Excludes those patients receiving a renal transplant.
Univariate analysis revealed that increasing age, co-
morbidity, including angina, mode of presentation, initial
mode of RRT, primary renal diagnosis group, short dura-
tion of follow-up by a nephrologist prior to RRT, and
initial serum albumin were all significantly associated
with death within 2 years of starting RRT. Low body
weight when starting RRT was also associated with in-
creased mortality, the average weight of those surviving
for 2 years or more after starting RRT was 70.7 kg (SD
16.0), compared with 67.3 kg (SD 14.2) (P  0.01, t test)
for those dying within 2 years. Gender and hemoglobin
concentration at the time of starting RRT did not have
a significant influence on survival in the univariate analy-
sis. A diagnosis of diabetes per se, irrespective of PRD,
did not influence 2-year survival; diabetes was only asso-
ciated with reduced survival when it was the cause of
renal failure (Table 4).
Mean attained hemoglobin, albumin and urea reduc-
tion ratio values over the first 2 years of treatment were
calculated from blood results at 3, 6, 9, 12, and 18 months
or until death. By necessity, patients dying within 90
days were excluded. The average attained levels over 18
months were divided into two groups, those on average
attaining the UKRA standards and those not. This was
taken as serum albumin 35g/L, hemoglobin 10 g/dL,
and urea reduction ratio 65% (Table 5).
A higher attained albumin and hemoglobin were asso-
ciated with survival in the univariate analysis both when
analyzed as continuous variables and when grouped into
average values falling above and below the recommended
standards of care. When the attained urea reduction ratio
of patients treated throughout their RRT career only
by hemodialysis were analyzed, a higher attained urea
reduction ratio was again associated with survival but
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Table 4. Patient characteristics when starting renal replacement therapy (RRT) and 2-year survival: Univariate analysis
Cohort 2-year mortality P value and
(N  523) number statistical test
Age group
15–49 years 119 15 (12.6%) P  0.001
50–64 years 150 48 (32.0%) 2
65–75 years 168 98 (57.7%)
75 years 86 57 (66.3%)
Gender
Males 311 126 (40.5%) P  0.6
Females 212 91 (42.9%) Fisher exact
Follow-up prior to RRT
0 to 1 month 133 77 (57.9%) P  0.001
2 to 3 months 51 29 (56.9%) 2
4 to 6 months 28 11 (39.3%)
7 to 12 months 53 17 (32.1%)
12 months 257 83 (32.3%)
Presentation
Planned 225 58 (25.8%) P  0.001
Unplanned 129 54 (41.9%) 2
Acute renal failure (no recovery) 53 36 (67.9%)
Acute on chronic 62 42 (67.7%)
End-stage renal disease 54 27 (50.0%)
First mode of RRT
Hemodialysis 400 187 (46.8%) P  0.001
Peritoneal dialysis 122 30 (24.6%) Fisher exact
Primary renal diagnosis
Glomerulonephritis 69 19 (27.5%) P  0.001
Interstitial disease 119 33 (27.7%) 2
Multisystem disease 78 57 (73.1%)
Hypertensive nephropathy 21 5 (23.8%)
Secondary glomerulonephritis 27 9 (33.3%)
Diabetic nephropathy 86 35 (40.7%)
Unknown 123 59 (48.0%)
Diabetes
Present 124 58 (46.8%) P  0.2
No 399 159 (39.8%) Fisher exact
Charlson score
0 194 34 (17.5%) P  0.001
1 102 53 (52.0%) 2
2 122 67 (54.9%)
2 105 63 (60.0%)
Angina grade
0 372 129 (34.7%) P  0.001
1–2 128 73 (57.0%) 2
3–4 23 15 (65.2%)
Serum albumin day 0
35 g/L 192 110 (57.3%) P  0.001
35 g/L 330 106 (32.1%) Fisher exact
Hemoglobin day 0
10 g/dL 329 142 (43.2%) P  0.3
10 g/dL 192 74 (38.5%) Fisher exact
this effect was not seen when grouped according to the
recommended standard of care.
Cox regression analysis was performed to identify
those factors significantly associated with death within
the first 2 years of RRT when all influences were taken
into account. Patients who died within the first 90 days
of treatment were excluded from the analysis, as were
those lost to follow up, those who received a transplant,
and those who recovered independent renal function.
A further 15 patients were excluded from the analysis
because they had incomplete records of albumin and/or
hemoglobin values over time precluding analysis as a
time related variable. Therefore, 381 patients were en-
tered into the analysis.
Age, Charlson grouping, body weight when starting
RRT, and attaining the recommended standards for al-
bumin and hemoglobin over the first 18 months of RRT
all had a significant impact upon survival over the first
2 years of RRT. The analysis was repeated with initial
values of hemoglobin and albumin (those at the time of
starting RRT) being retained within the Cox regression
model, in order to exclude the possibility that attained
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Table 5. Treatment standards attained averaged from 3, 6, 9, 12, and 18 months results: Univariate analysis
2-year mortality P value and
Cohort (N  396) number (%) statistical test
Mean serum albumin
3–18 months g/L 36.19 SD 4.36 33.97 SD 4.99 P  0.001a
t testa
Mean albumin
35 g/L 274 (69.9) 71 (25.9%) P  0.001
35 g/L 118 69 (58.5%) Fisher exact
Mean hemoglobin
3–18 months g/dL 10.4 SD 1.4 9.9 SD 1.3 P  0.001a
t test
Mean hemoglobin
10 g/dL 256 66 (25.8%) P  0.001
10 g/dL 137 75 (44.7%) Fisher exact
Mean urea reduction ratio (N  257) (N  103) P  0.05a
3-18 months 66.0 SD 6.9 64.9 SD 7.9 t test
Mean urea reduction ratio
65% 142 53 (37.3) P  0.4
65% 115 50 (43.5) Fisher exact
Urea reduction ratio figures calculated only for those patients treated exclusively by hemodialysis (excludes patients dying within 90 days and patients receiving
a renal transplant).
a P values relate to the difference between survivors and nonsurvivors at 2 years
Table 6. Cox regression survival analysis of the first 2 years of renal replacement therapy (RRT)
Odds ratio 95% CI for odds ratio Significance
Attaining albumin standard 0.40 0.28–0.57 P  0.0001
Attaining hemoglobin standard 0.69 0.49–0.98 P  0.04
Age (additional year) 1.03 1.02–1.05 P  0.0001
Charlson group
0 Ref — P  0.002
1 1.79 1.04–3.07
2 2.41 1.43–4.05
2 2.60 1.52–4.45
Weight at day 0 (kg) 0.98 0.97–0.99 P  0.02
Initial albumin 0.92 0.64–1.30 P  0.6
Initial hemoglobin 1.10 0.76–1.58 P  0.6
levels simply reflected initial values. The same factors
were significant (Table 6).
Attaining the recommended standards (analyzed as a
time-related variable over the first 18 months of RRT)
for albumin (odds ratio 0.4, P 0.0001) and hemoglobin
(odds ratio 0.69, P  0.04) was associated with a 60%
and 31% reduction in the risk of death, respectively,
compared with those failing to attain the standards.
Age (odds ratio 1.03, P  0.0001), Charlson grouping
(odds ratios 1.79, 2.41, 2.60, respectively, P  0.002) and
weight when starting RRT (odds ratio 0.98, P  0.02)
also had a significant impact upon survival.
Each extra year of age at the time of starting RRT
increased the likelihood of death over 2 years by 3%.
Compared with patients with no comorbidity at the time
of starting RRT, those scoring 1 on the Charlson score
had a 79% increase in the risk of death; those scoring 2
had a 141% increased risk of death, and those scoring
over 2 a 160% increased risk of death within the first 2
years of treatment. Each extra kilogram in body weight
at the time of starting RRT reduced the risk of death
over 2 years by 2%.
Neither albumin nor hemoglobin at the time of starting
RRT had a significant influence upon survival over 2
years when all other factors were considered but attained
levels of each had significant influence. Patients’ gender,
mode of presentation for RRT, duration of care by a
nephrologist prior to starting RRT, and severity of an-
gina had no impact upon survival over 2 years when
considered along with the factors above.
The same Cox regression analysis was performed to
analyze survival of those patients treated only by hemo-
dialysis from the time of initiation of RRT until the
completion of 2 years of treatment or death (N  241).
Time-related attained urea reduction ratio was included
in the analysis along with those variables discussed above.
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Table 7. Cox regression survival analysis of the first 2 years of renal
replacement therapy patients treated only by hemodialysis
Odds 95% CI
ratio for odds ratio Significance
Attaining albumin standard 0.36 0.24–0.55 P  0.0001
Age (additional year) 1.03 1.01–1.05 P  0.01
Charlson group
0 Ref — P  0.02
1 2.18 1.15–4.16
2 2.35 1.23–4.48
2 2.78 1.46–5.27
Initial albumin 0.85 0.56–1.28 P  0.4
The analysis showed that those factors with significant
impact upon survival over the first 2 years of RRT in
this group were age, Charlson grouping, and attaining
the recommended standard for serum albumin over time.
The analysis was repeated forcing initial albumin to re-
main within the model and those factors with significant
impact were unchanged (Table 7). Attaining the recom-
mended albumin standard was associated with a 64%
reduction in the odds of death compared with those
failing to meet the standard (odds ratio 0.36, P 0.0001).
Comorbidity score on the Charlson scale was associated
with increased risk of death of 2.18, 2.35, and 2.78, respec-
tively, for patients scoring 1, 2, and 2 compared with
those with no comorbidity (P  0.02). Each extra year
of age at the time of starting RRT increased the likeli-
hood of death over 2 years by 3% (odds ratio 1.03, P 
0.01). Attaining the urea reduction ratio standard over
time did not significantly influence survival when consid-
ered in association with all other factors.
DISCUSSION
This study demonstrates the high mortality of patients
starting RRT for ESRD. Gross mortality after 1 year
was 27.5% and after 2 years was 41.5%. When deaths
within the first 90 days of treatment were excluded, mor-
tality rates were 15.8% and 32%, respectively.
A previous retrospective Scottish study of patient
starting RRT between 1985 and 1991 reported mortality
of 39% at 2 years, 27% excluding deaths within 90 days
[9]; therefore, no improvement in unadjusted survival in
this current study is seen. Other United Kingdom studies
report 1-year mortality to range between 17.5% and 24%
[14, 15]. United Kingdom Renal Registry data report
1- and 2-year mortality of the cohort of patients starting
RRT in 1998 at 24% and 36%, respectively, these figures
include deaths within the first 90 days [16]. The slightly
worse survival reported in this study, compared with the
overall United Kingdom survival, may be due to the
higher incidence of patients starting RRT in Scotland. In
1998, 102 patients per million population (pmp) started
RRT [17] compared with 89 pmp in England and Wales
[18]. The additional patients in Scotland are likely to be
older than average with greater comorbidity. In addition,
the prospective methods employed for this study ensure
complete recording of all relevant patients. Patients miss-
ing from retrospective and registry data are likely to be
those who die soon after starting RRT.
The USRDS report of 1998 shows 1-year mortality
(excluding 90-day deaths) to have fallen from 26% in
1988 to 23% in 1995 [19]. Survival of patients treated by
RRT in the United States is consistently worse than in
Europe or Japan for reasons that probably relate both
to processes of care as well as patient mix [20, 21]. The
majority of large studies examining influences upon the
survival of the RRT population have been performed in
the United States. Survival and nephrologic practice in
the United Kingdom differ from the United Kingdom,
therefore data pertaining to the North American popula-
tion do not necessarily apply to the United Kingdom
hence the need for this study.
This study, taking into account patient comorbidity,
demonstrates for the first time in United Kingdom pa-
tients starting RRT, that attaining the UKRA-recom-
mended standards of hemoglobin concentration and al-
bumin is associated with improved survival.
Hemoglobin concentration at the time of starting RRT
did not significantly impact upon survival; however, at-
taining a mean hemoglobin over 18 months of RRT of
10 g/dL was associated with a 31% reduction in the risk
of death over 2 years when analyzed using multivariate
methods.
Anemia has previously been shown to have an adverse
impact upon exercise tolerance, quality of life, hospital-
ization rates, and left ventricular dysfunction and hyper-
trophy. Left ventricular hypertrophy is an independent
predictor of mortality in patients with ESRD [22]. Foley
at al [23] demonstrated anemia in dialysis patients is
independently associated with left ventricular dilatation
and the development of de novo and recurrent cardiac
failure. Previous studies have also shown survival of dial-
ysis patients declines as hemoglobin decreases [23–25]
but none corrected for comorbidity, albumin, and other
variables.
Low serum albumin is associated with mortality in
the general population as well as in a variety of patient
populations [26]. Low serum albumin has consistently
been found to predict mortality in patients receiving
either peritoneal dialysis or hemodialysis [20, 27–31].
When analyzed by univariate methods, a low serum
albumin when starting RRT was associated with death
within 2 years. However, when analyzed by multivariate
methods, the degree of hypoalbuminaemia at the time
of starting RRT did not have a significant effect upon
2-year survival, but attaining an albumin that met the
recommended standard ( 35 g/L) decreased the risk of
death by 60%. Among patients treated only by hemodial-
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ysis, the decrease in the odds of death was 64% for those
attaining the recommended standard.
We did not find that attaining recommended urea re-
duction ratio standards conferred a survival benefit de-
spite a benefit of higher urea reduction ratio when ana-
lyzed by univariate methods. This may be because only
257 patients had only been treated by hemodialysis and
were therefore eligible for analysis of the influence of
urea reduction ratio. However, in contrast to previous
studies that have demonstrated a survival benefit of in-
creasing urea reduction ratio, it was the aim of treatment
for all patients to have a urea reduction ratio of 65%;
therefore, the mean urea reduction ratio of the cohort
was 66; SD 6.9. There was little variation in the attained
urea reduction ratio for the majority of patients and thus
other influences upon survival, such as comorbidity, had
greater impact.
There is evidence, again mainly from North America,
that survival of patients on hemodialysis is positively
associated with high interdialytic removal of low-molecu-
lar-weight toxins, of which urea is an easily measured
surrogate [20, 28, 32–38]. The evidence that improving
such adequacy of dialysis in patients treated by perito-
neal dialysis is less consistent, but the CANUSA study
reported this to be the case [30]. Differing survival rates
between American dialysis centers have also been shown
to correlate with the average urea reduction ratios at-
tained in each center [39].
The major impact of comorbid illness on survival of
patients treated by RRT is demonstrated by this study.
Both in the cohort as a whole and the subset treated
exclusively by hemodialysis, increased comorbidity was a
strong predictor of poor outcome. Compared with those
with no comorbid illnesses, patients scoring more than
2 on the Charlson scale had 2.6 times the odds of death
over 2 years when all other factors had been taken into
account.
The adverse effect of comorbidity upon survival of
patients on RRT is well documented [9, 40–42]. The
challenge is to adopt a method of recording comorbidity
uniformly in a straightforward manner so that survival
statistics can be meaningfully compared between patient
groups and units providing RRT. The Charlson index of
comorbidity is a widely used tool in areas other than
ESRD. It has been used in previous studies of patients
with ESRD and found to predict survival in patients
treated both by peritoneal dialysis [43] and a cross-sec-
tion of patients treated by hemodialysis [44]. The Charl-
son index is unambiguous and straightforward to use,
thereby providing a uniform, reproducible score of co-
morbidity.
Patient’s primary renal diagnosis did not significantly
influence mortality when considered in association with
all other factors however several primary renal diagnoses
imply comorbid illnesses. The multisystem disease group
consisted largely of those with renal failure as a conse-
quence of multiple myeloma or atherosclerotic renal ar-
tery disease. Five percent of total deaths in this study
were due to myeloma. This poor prognosis is reflected
in a retrospective study of USRDS data, which reported
a 58% 2-year mortality for patients with myeloma com-
pared with 31% in all other patients [45]. The proportion
of patients starting RRT who have atherosclerotic reno-
vascular disease causing their renal failure is increasing;
anecdotally, they are also assumed to comprise a large
proportion of patients in whom a definitive diagnosis is
not possible. Such patients are also likely to have coro-
nary heart disease, peripheral vascular disease, and
cerebrovascular disease [46].
Greater body weight when starting RRT was demon-
strated to confer a survival benefit, each extra kilogram
in weight reducing the odds of death within 2 years by
2%. We did not have any further information available
from which an estimation of body mass index or lean
body mass could be calculated and therefore the signifi-
cance of this finding is difficult to qualify. It is possible
that body weight is acting as a crude marker of nutrition.
Poor nutritional status has been described to be a poor
prognostic indicator for patients treated by RRT [29, 31,
47]. Examination of the data suggested that body weight
was not simply a surrogate marker of either gender or
serum albumin since there was no consistent relationship
between weight and these variables.
This study has emphasized the very high mortality of
patients starting RRT in Scotland. Age, comorbidity,
and attaining recommended standards of care for hemo-
globin and serum albumin are the major factors affecting
survival of patients receiving RRT. This information is
important for nephrologists and generalists alike in order
to inform discussions with patients and their relatives,
and thus prevent unrealistic expectations of outcomes
on RRT. RRT is truthfully described as a life-saving
treatment, those with ESRD cannot survive without it;
however, the effect of comorbid illnesses must be consid-
ered.
In all observational studies of this type, causality can-
not be deduced and hence we have been careful to report
associations and not infer causality. The correlation be-
tween attainment of standards and outcomes, however,
remains significant after all efforts were made to adjust
for confounding factors. It is by refining the data ele-
ments collected in observational studies, including co-
horts of patients systematically reported by registries,
that we can improve upon the information they provide.
This study highlights not only the need for comorbidity
to be taken into account but also the necessity of finding
a practical method for routinely doing so, including the
definition of a minimum data set for comorbidity that
will reflect outcomes.
By paying close attention to the attainment of recom-
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mended standards of care for patients with ESRD it may
be possible to improve upon current mortality figures.
However, the monitoring of such success is only possible
if correction is made for age, comorbidity, and serum
albumin. A uniform method of adjusting for comorbidity
should be adopted in order to allow for direct compari-
son of outcomes between patient groups, facilities pro-
viding RRT, and internationally.
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